On Tuesday, AlphaValue raised its recommendation on Ipsen shares to 'buy' from 'accumulate', citing an 'attractive small pharma stock'.

After a promising end to the 2022 financial year, followed by a vigorous performance in the first half, we are raising our price target by 23%, thanks to a robust pipeline combined with encouraging clinical results in recent months, favorable trials expected in the coming months and a solid balance sheet', it concludes.

Its target thus rises to 168 euros from 137 euros previously.

Copyright (c) 2023 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.